Stefan_Ochiana
Stefan O. Ochiana, Ph.D.
Associate
More
vCard
  • 901 New York Avenue, NW
  • Washington, DC 20001-4413

Stefan O. Ochiana, Ph.D.

Associate

  • 901 New York Avenue, NW
  • Washington, DC 20001-4413
Stefan_Ochiana
Stefan Ochiana, Ph.D., prosecutes and provides strategic counseling on U.S. and foreign patent portfolios in the chemical and pharmaceutical arts. His experience also includes assisting with Abbreviated New Drug Application (ANDA) litigations under the Hatch-Waxman Act, inter partes review (IPR) proceedings at the U.S. Patent and Trademark Office (USPTO), and disputes in district courts across the country.

Prior to joining Finnegan, Stefan worked as a post-doctoral research scholar at Memorial Sloan Kettering Cancer Center. His work included several projects aimed at the discovery and development of heat shock protein 90 (Hsp90), Hsp70, glucose-regulated protein 94 inhibitors, and the design and synthesis of chemical probes for the biological evaluation of these targets.

Stefan's graduate dissertation research focused on the design, synthesis, and evaluation of human aurora kinase and phosphodiesterase inhibitors for anti-trypanosomal drug discovery via target repurposing. Stefan has a wide range of technical experience, including the areas of organic and medicinal chemistry, computational chemistry, drug delivery, preclinical drug development, and chemical biology. He has authored or co-authored eighteen journal papers and a book chapter, presented his research at thirteen national and local conferences, and is a co-inventor on many patent applications related to his postdoctoral work.

Et Cetera

  • American Cancer Society Postdoctoral Fellowship, 2014.
  • Dissertation Completion Fellowship, Office of the Provost, Fall 2012.
  • Coauthor. "Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system," Nature Communications, 2021.
  • Coauthor. "First in-Human Trial of Epichaperome-Targeted Positron Emission Tomography in Cancer Patients," Clinical Cancer Research, 2020.
  • Coauthor. "Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not," Proceedings of the National Academy of Sciences, USA, 2015.
  • Coauthor. "Structure-Activity Relationship in a Purine-Scaffold Compound Series with Selectivity for the Endoplasmic Reticulum Hsp90 Paralog Grp94," Journal of Medicinal Chemistry, 2015.
  • Coauthor. "Selective Targeting of the Stress Chaperome as a Therapeutic Strategy," Trends in Pharmacological Sciences, 2014.
  • Coauthor. "Heat Shock Protein 90 Inhibitors in the Treatment of Cancer: Current Status and Future Directions," Expert Opinion on Investigational Drugs, 2014.
  • Coauthor. "Designing Drugs Against Hsp90 for Cancer Therapy," The Molecular Chaperones Interaction Networks in Protein Folding and Degradation, Sept. 2, 2014.
  • Coauthor. "The Human Aurora Kinase Inhibitor Danusertib Is a Lead Compound for Anti-Trypanosomal Drug Discovery Via Target Repurposing," European Journal of Medicinal Chemistry, 2013.

Experience

Sandoz, Inc. et al v. Pharmacyclics LLC

Represented patent owner in inter partes review (IPR) challenge related to Imbruvica® (ibrutinib) for the treatment of chronic graft versus host disease.

IPR2019-00865, PTAB, Judges Cotta, Snedden, Mitchell

Closure Systems International v. Novembal USA, Inc.

Represented Novembal USA, Inc., the declaratory judgment defendant, in this multi-design patent case directed to designs for closures for bottles. This case favorably settled during discovery.

1:19-cv-03944, S.D. Ind., Judge Dinsmore

Salient Systems Corporation v. Hawk Technology Systems LLC et al.

Represented Salient Systems in litigation against Hawk Technology Systems. Salient Systems’ Complaint alleged breach of contract, breach of covenant of good faith and fair dealing, fraud, tortious interference with business relations, patent invalidity, patent misuse, and violations of the Sherman Act. The Chief Judge ruled in Salient’s favor on Hawk’s dispositive motion against Salient’s Complaint, denying Hawk’s motion in its entirety.

1:20-cv-01558, D. Del., Judge Connolly

Hawk Technology Systems, LLC v. Tyler Stonegate Property Owners Association, Inc.

Represented Tyler Stonegate Property Owners Association in patent litigation brought by Hawk Technology Systems, resulting in dismissal of the case.

6:20-cv-00572, E.D. Tex., Judge Barker

Hawk Technology Systems, LLC v. Castle Retail, LLC

Represents Castle Retail in patent litigation brought by Hawk Technology Systems. Judge McCalla ruled in Castle Retail’s favor, granting Castle Retail’s Rule 12 motion and invalidating Hawk’s patent claims. The case is currently on appeal before the Federal Circuit.

2:20-cv-02766, W.D. Tenn., Judge McCalla

Hawk Technology Systems, LLC v. Kirkland's Inc.

Represented Defendant Kirkland’s and Intervenor Salient Systems in patent litigation brought by Hawk Technology Systems. The case was dismissed with prejudice.

3:20-cv-00276, N.D. Miss., Judge Mills

More

News

Announcement

Finnegan Announces 2019 Mentors of the Year Finnegan Announces 2019 Mentors of the Year

December 30, 2019

Professional Activities

  • American Bar Association
  • American Chemical Society
Admissions and Education

Admissions

  • District of Columbia
  • Massachusetts
  • U.S. Court of Appeals, Federal Circuit
  • U.S. Patent and Trademark Office

Education

George Washington University Law School
J.D., with honors, 2021
Northeastern University
Ph.D., Organic Chemistry, 2013
Saint Vincent College
B.S., Biochemistry, 2008

Languages

  • Romanian

Stefan's Practices

Patent Litigation
Branded Hatch-Waxman (ANDA)
Patent Office Examinations
Prosecution
Patent Portfolio Management, Monetization, and Transactions
Due Diligence
Opinions and Counseling
Patent Mining and Mapping
Post-Grant Proceedings
IPR, PGR, and CBM

Stefan's Industries

Chemicals, Industrials, and Materials
Chemical
Life Sciences
Biotechnology
Pharmaceutical

Due to international data regulations, we’ve recently updated our privacy policy. Click here to read our privacy policy in full.

We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.

The Finnegan UPC Hub is a one-stop shop for our insights related to the Unified Patent Court (UPC).

Click Here